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a b s t r a c t
The inﬂexibility of existing serological techniques for detection of rabies in surveillance constrains the
beneﬁt to be gained from many current control strategies. We analysed 304 serum samples from Tanza-
nian dogs for the detection of rabies antibodies in a pseudotype assay using lentiviral vectors bearing the
CVS-11 envelope glycoprotein. Compared with the widely used gold standard ﬂuorescent antibody virus
neutralisation assay, a speciﬁcity of 100% and sensitivity of 94.4% with a strong correlation of antibody
titres (r=0.915)were observedwith the pseudotype assay. To increase the assay’s surveillance speciﬁcity
in Africa we incorporated the envelope glycoprotein of local viruses, Lagos bat virus, Duvenhage virus
or Mokola virus and also cloned the lacZ gene to provide a reporter element. Neutralisation assays using
pseudotypes bearing these glycoproteins reveal that they provide a greater sensitivity compared to sim-
ilar live virus assays and will therefore allow a more accurate determination of the distribution of these
highly pathogenic infections and the threat they pose to human health. Importantly, the CVS-11 pseu-
dotypes were highly stable during freeze–thaw cycles and storage at room temperature. These results
suggest the proposed pseudotype assay is a suitable option for undertaking lyssavirus serosurveillance
in areas most affected by these infections.
© 2009 Elsevier Ltd. All rights reserved.
1. Introduction
Rabies is spreading at an alarming rate in some regions of the
developing world [1–3]. Collaborative efforts among human and
animal healthcare professionals are required to monitor this situ-
ation and allow a timely and proportioned therapeutic response,
limiting unnecessary use of valuable vaccines. The combination
of rabies awareness campaigns, improved vaccine coverage and
disease surveillance has already resulted in the successful elimi-
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nation of canine rabies in North America [4]. However, vaccines
need to be efﬁcacious enough to elicit a response that will con-
fer protection and diagnostic techniques are needed to ensure
that adequate levels of virus-neutralising antibodies (VNAbs) have
been achieved in response to vaccination. The problem with cur-
rent tests is that they are not easily used in endemic areas within
developing countries because they need to be set up in contain-
ment laboratories since highly pathogenic zoonotic viruses are
required to perform the assay, or such assays are prohibitively
expensive. Those that are e.g., ELISA-based assays, do not have the
sensitivity or speciﬁcity of the ﬂuorescent antibody virus neutrali-
sation (FAVN) assay that is widely used within Ofﬁce international
des épizooties (OIE) rabies reference laboratories. Therefore, in
addition to the need for further implementation and develop-
ment of improved anti-rabies biologicals, improved techniques to
assess seroconversion are required before canine rabies is success-
0264-410X/$ – see front matter © 2009 Elsevier Ltd. All rights reserved.
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Fig. 1. Overview of vaccination trial. (A) As part of an annual rabies vaccination campaign run by the Viral Transmission Dynamics Project, 191 dogs from four villages
(Ngarawani [NG], Runga’bure [RNG], Nyamburi [NY] and Bisarara [BS]) near the north western border of the Serengeti National Park were enrolled in this study. The inset
shows a larger scale map detailing the location of the four villages. (B) The owners were invited to bring their dogs to two sessions. During the ﬁrst, samples were collected
for baseline measurements, a rabies vaccine was administered and a welfare assessment conducted. Twenty-one days later (* the revisit to BS village was 20 days post-
vaccination) the dogs had further samples collected. (C)While all sampleswere processed using the same protocol, the levels of haemolysis and serum collectedwere variable
but did not affect results.
fully eliminated in developing countries as it has been in North
America.
Within the Lyssavirus genus, classical rabies viruses (genotype
1) are not the only pathogen to cause morbidity and mortality in
mammalian populations. Clearly, infection by lyssaviruses of the
other genotypes (2–7) can result in a clinical manifestation that is
indistinguishable from rabies. The other genotypes are distributed
geographically predominantly within African, European and Aus-
tralian bat populations [5]. Recently, additional variants that are
more divergent than genotypes 1–7 have been isolated suggest-
ing further genotypes may yet exist [6–10]. Isolates representing
genotypes 1, 2 and 4–7 have been identiﬁed in insectivorous, fruit
or vampire bats [5]. Mokola virus (MOKV, genotype 3) along with
Lagos bat virus (LBV, genotype 2) and Duvenhage virus (DUVV,
genotype 4) comprises the African lyssaviruses. Interestingly, only
a fewclinical isolates representing thesegenotypeshavebeen iden-
tiﬁed to date [11]. The handful of cases that have been reported has
given us a limited understanding of the epidemiology and zoonotic
threat that these genotypes pose in their respective hosts. Recently,
surveillance programs and greater access to serosurveillance tech-
niques have resulted in the discovery of a high seroprevalence
against LBV in East and West African megachiroptera [12,13] and a
commonpresence of LBV in South African bats collected for routine
surveillance [11].
These reports and others [2,14] emphasise that the potential for
increased incidence levels of rabies and related lyssavirus infec-
tions is a concern in Africa, mainly because of the lack of awareness
of these infections in the population. However, there is also poor
accessibility to vaccines and post-exposure treatments for those
exposed to these viruses and there are difﬁcultieswith undertaking
(sero)surveillance measures in many countries within Africa [15].
While the most important factor in reducing rabies prevalence is
the implementation of vaccination campaigns, it was highlighted
at the recent Southern and Eastern African Rabies Group meeting
that poor infrastructure becomes a major barrier when attempting
to control rabies in Africa [16]. These views are shared by the OIE
and World Health Organization (WHO), that list the development
of novel diagnostics as an urgent requirement [17,18].
Serological techniques that can be employed to study natu-
rally occurring or vaccine-induced humoral responses to rabies
virus infection include the FAVN assay [19], rapid ﬂuorescent focus
inhibition test (RFFIT) [20] and enzyme linked immunosorbant
assay (ELISA) [21]. Variations of these assays have been described
previously [22,23]. The routinely used FAVN assay and RFFIT are
the current assays of choice with OIE/WHO reference laboratories
but must be performed in BSL3/SAPO4 high containment facili-
ties because live virus is handled as part of the assay. While a
modiﬁed RFFIT that combines green ﬂuorescent protein (GFP) with
live recombinant virus can remove the need for expensive conju-
gates, work with recombinant virus still requires the use of high
containment facilities [23]. With the recent addition to the above
mentioned set of neutralisation assays of the ELISA-based method
that uses plates coated with whole, inactivated virus, the need for
live virus has been eliminated. Since both non-neutralising and
neutralising antibodies are detected, the level of circulating, pro-
tective VNAbs alone cannot be determined. There are also issues
with low sensitivity when using the ELISA.
We recently described the use of surrogate viruses known as
lentiviral pseudotypesas replacements for liveor inactivatedwhole
virus to accurately determine anti-rabies VNAb responses in vac-
cine recipients. The samples tested were taken from vaccinated
humans, dogs and cats in the United Kingdom (UK) [24]. Here we
report the results of the largest virus neutralisation study pub-
lished to date using the surrogate lentiviral pseudotypes rather
than the live native or recombinant rabies virus with ﬁeld serum
samples from Tanzanian dogs. We further increase the utility of
our pseudotype neutralisation assay for laboratories undertak-
ing vaccine trials and serosurveillance in resource-limited, rabies
endemic countries by exploring the use of lacZ as a reporter gene
and incorporating the glycoproteins of a further three lyssavirus
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Table 1
Details of dogs enrolled from each village for this study.
Village Mean age (years) Gender (% female) Number of sera collected Vaccination history at 1st visit (n/%)
First visit Second visit Primary Booster No record
Ngarawani 2.1 47.9 48a 37 31/64.6 6/12.5 11/22.9a
Runga’bure 2.65 48 50 38 20/40.0 27/54.0 3/6.0
Nyamburi 1.4 54.2 48 26 41/85.4 7/14.6 0/0.0
Bisarara 1.56 55.6 45b 29 33/73.3 12/26.7b 0/0.0
TOTAL 1.94 51.3 191 130 125/65.5 52/27.2 14/7.3
“Primary” refers to dogs that had never received a rabies vaccination prior to this study, “booster” refers to dogs that had previously received ≥1 rabies vaccination and “no
record” means there was no vaccination history available or taken.
a One sample was missing on arrival in the UK.
b One sample vial was empty on arrival in the UK.
genotypes, in addition to genotype 1, which will allow improved
serosurveillance for lyssaviruses other than classical rabies. This
report describes a highly sensitive yet ﬂexible platform that
can be adapted to allow the evaluation of vaccine and antivi-
ral drugs against highly pathogenic viruses without the need
for high level containment facilities or expensive reagents and
equipment.
2. Methods
2.1. Study area
Dogs enrolled in this study were selected from domestic ani-
mals living in four villages (Ngarawani, Runga’bure, Nyamburi and
Bisarara) within 20km of the Serengeti National Park perimeter
in the Serengeti District, northwestern Tanzania (Fig. 1A). In each
case the dog owner’s consent was sought before enrolling their
dog in the study. This project was part of the annual vaccination
campaign undertaken by the Viral Transmission Dynamics Project,
whichworks to prevent the spread of diseases through animal pop-
ulations in the Serengeti region.
2.2. Vaccination history
A detailed medical history of each dog enrolled in this study,
which included any prior vaccinations, was taken at the ﬁrst visit.
Sixty-six and a half percent (n=125) of the dogs had not been vac-
cinated against rabies prior to this study (referred to as “primary”),
27.2% (n=52) had received at least one rabies vaccine previously
(“booster”) and there was no vaccination history available or taken
for 7.3% (n=14; “no record”; Table 1). The Nobivac® rabies virus
vaccine (donated by Intervet Schering-Plough Animal Health) was
administered to all dogs in a single dose inoculation given subcuta-
neously. It comprises an inactivated vaccine containing >2 IU rabies
virus (Pasteur strain).
2.3. Serum samples
At the ﬁrst visit, a blood sample was taken from each dog
before the rabies virus vaccine was administered. The second visit
was 20–21 days post-vaccination, the optimum time to detect an
immune response stimulated by the vaccine. The overall study pro-
tocol is shown in Fig. 1B.
Blood was drawn from the cephalic or jugular vein, stored
on ice, and processed at the end of each day (centrifugation at
3000 rpm for 10min). Serum was prepared, inactivated at 57 ◦C
for 30min and then frozen for transport. In total, 321 samples
were taken from the enrolled dogs, blinded and sent to Univer-
sity College London (UCL) and Veterinary Laboratories Agency
(VLA) for testing. The OIE standard reference dog serum diluted to
0.5 international units/ml (IU/ml) with PBS was used as a positive
control.
Rabbit anti-sera raised against LBV isolate RV1 (n=2) and DUVV
isolateRV131 (n=4)wereused inneutralisationassayswithAfrican
lyssavirus pseudotypes. Anti-sera to MOKV were not available but
anti-LBV serum is known to cross-neutralise MOKV. One serum
raised against uninfected tissue culture supernatant and another
against Australian bat lyssavirus (RV634) were used in the same
panel as the LBV and DUVV sera.
2.4. Infection and neutralisation assays
Human embryonic kidney 293T cells [25] were used for pro-
duction of the lentiviral pseudotypes (lyssavirus surrogates).
Neutralisation assays were undertaken on baby hamster kidney 21
cells clone 13 (BHK; [26]). The NP2 human glioma cell line express-
ing CD4 and CXCR4 was used as target cells for HIV-1 pseudotypes
[27].
2.4.1. FAVN assays
Live virus experiments were undertaken using a restricted ver-
sion of the FAVN that is identical to the existing FAVNassay [19] but
with serum samples diluted 3-fold to a ﬁnal titre of 1:81, roughly
equivalent to 5.92 IU/ml.
2.4.2. Pseudotype assays
Standard plasmids and the transfection protocol for lentiviral
pseudotype (lyssavirus surrogate) production have been described
elsewhere [24]. Additionally, glycoprotein (G) gene sequences
from LBV (LBV.SA2004; accession number EF547428), MOKV
(MOKV.98/071 RA361; accession number GQ500108) and DUVV
(DUVV.RSA2006; accession number EU623444) were ampliﬁed
by PCR using speciﬁc primers (detailed in Supplementary Table
S1). Pseudotypes containing the HIV-1 envelope gp160 gene were
generated using pSVIIIenv [28]. G gene sequence analysis was
undertaken using ClustalW [29] and Treeview [30].
Infection and neutralisation assays using lyssavirus pseudo-
types were performed as previously described [24] with the
following three modiﬁcations: (1) plates were centrifuged at
500 rpm for 10 s after the virus was added and once more follow-
ing addition of BHK cells; (2) to ensure the OIE standard reference
dog serum recorded an IC100 at a 1:40 dilution, approximately 30×
TCID50 of pseudotype was used; (3) serum was diluted 5-fold to a
ﬁnal titre of 1:640.
2.5. Pseudotype reporter genes
2.5.1. ˇ-Galactosidase
To enable pseudotype particle detection using the appropri-
ate -galactosidase (-gal) substrates, we constructed pCSLZW,
which contains the lacZ gene from pMFG-nls-lacZ (a kind gift
from Dr. Yasuhiro Takeuchi; [31]) cloned into pCSGW (primers
detailed in Supplementary Table S1). Where -gal was the
reporter protein, -gal-pseudotype-infected cells were detected
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Fig. 2. Strong correlation between FAVN and pseudotype neutralising antibody titres using Tanzanian dog sera. (A) Neutralising titres achieved with the pseudotype assay
increase concordantly with those detected in the FAVN assay. The distribution, according to VNAb titres determined by the (B) pseudotype and (C) FAVN assays, of sera
collected at the ﬁrst visit from primary (dogs that had not received a previous rabies vaccination—black columns), booster (dogs that had received ≥1 rabies vaccination
previously—grey columns) or dogs with no vaccination record (white columns) is shown. Similar analyses for samples collected at the second visit are shown in (D) and (E)
for the pseudotype and FAVN assays, respectively. The dotted line marks the level of VNAb that was achieved by the OIE positive control serum. Percents of samples with
an inadequate or adequate VNAb response are given left and right of the dotted line, respectively. Vaccination history was available for 169 dogs (ﬁrst visit: primary n=119,
booster n=50, no record n=13; second visit: primary n=84, booster n=37, no record n=1). (F) Results from the pseudotype neutralisation and FAVN assays reveal a high
degree of concordance (Sn: sensitivity and Sp: speciﬁcity) and a strong correlation (r) between titres. Sn and Sp are relative to the 0.5 IU/ml threshold and r/p values were
calculated using Pearson’s product–moment correlation. Arrows indicate VNAb titres for which there were no serum samples containing that level of antibodies.
using 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside (X-
gal; Sigma), chlorophenol red-beta-d-galactopyranoside (CPRG;
Sigma) or o-nitrophenyl-b-d-galactopyranoside (ONPG; Sigma).
Detection using the X-gal substrate was accomplished by ﬁx-
ing the infected cell monolayer and then staining the cells with
substratebuffer (10mMdeoxycholic acid, 5mMpotassiumferrocy-
nate, 5mMpotassium ferricynate, 4.3mMmagnesiumchloride and
0.02% (v/v) NP40) containing 1mg/ml X-gal. For CPRG and ONPG
substrates, nuclei were lysed and 50l of reaction buffer (120mM
Na2HPO4·2H2O, 80mM NaH2PO4·H2O, 2mM MgCl2, 100mM -
mercaptoethanol) was added containing CPRG or ONPG at a ﬁnal
concentrationof29.2and1.3mg/ml, respectively. This reactionwas
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Table 2
Distribution of sera according to FAVN neutralising antibody titre.
Percentages given are the proportion in that category out of the total number for
the column.
aSamples that were positive by FAVN assay but negative by the pseudotype assay.
inhibited, after 1–2h at 37 ◦C, by adding stop solution (1M sodium
carbonate).
2.5.2. GFP and luciferase
GFP and luciferase reporter genes were employed to detect
GFP-positive cells,whichwerevisualisedusingaﬂuorescentmicro-
scope and FACSCalibur (BD Biosciences) and luciferase expression,
which was detected using the Bright-Glo reagent and GloMax 96
microplate luminometer (Promega).
3. Results
3.1. Serum samples analysed
Of the 191 dogs enrolled in this study, the mean age was 1.94
years and 51.3% were female (Table 1). In total, 321 samples were
takenduringbothvisits (Table1).However, in transport one sample
disappeared (#27) and one leaked so no serum remained (#192).
Of the remaining 319 samples, the volume in 12 was too small to
test in the FAVN assay and a further three samples could not ini-
tially be tested in the pseudotype assays because of contamination
and toxicity. The remaining 304 samples were tested in both assay
types.
While the serum process times were kept as constant as possi-
ble there were varying degrees of haemolysis and volumes of sera
produced varied with each collection (Fig. 1C). Haemolysis did not
affect the results obtained with either the FAVN or the pseudotype
assays.
3.2. Sensitivity and speciﬁcity of CVS-11 pseudotypes using
Tanzanian canine sera
Sera that failed to achieve an antibody titre of 1:10 by the pseu-
dotype assay, the lowest recordable result from the dilutions that
were used, were given an arbitrary titre of 1:5 for this analysis.
The OIE positive control serum routinely neutralised 100% of CVS-
11 pseudotype particles at a dilution of 1:40 (in this study the OIE
mean dilution=37.5 and standard deviation=±14.4) and 100% of
live CVS-11 at a dilution of 15.59, normally equivalent to 0.5 IU/ml,
for the FAVN assay (in this study the OIE mean dilution=17.2 and
standard deviation=±4.0). The lowest titre a serum sample was
given by the FAVN assay in this study is 0.07 IU/ml. Any dogs with
VNAb levels that attained an IC100 at a dilution of greater than or
equal to 1:40 (by pseudotype assay) or a titre of 0.5 IU/ml (by FAVN
assay) were considered positive (also referred to as “adequate” in
this study).
When results from the FAVN and pseudotype assays were com-
pared, we observed a concurrent increase in VNAb titres reported
by the pseudotype assay as the FAVN titre increased (Fig. 2A).
There were 17 discordant samples, classiﬁed as negative by the
pseudotype assay but positive with the FAVN assay (Table 2). As
a result, the average titre of samples classiﬁed as borderline pos-
itive by the FAVN assay (0.5 IU/ml) is 1:25, a borderline negative
result with the pseudotype assay. While these discordant samples
reduced the sensitivity of the pseudotype neutralisation assay to
94.4%, the speciﬁcity of the assay was 100% (n=304). The majority
of the discrepancies clustered around 0.5 IU/ml, the titre achieved
using the OIE positive control serum and currently used to clas-
sify VNAb responses as inadequate (levels below that achieved by
the OIE positive control serum) or adequate (levels greater than or
equal to that achieved by theOIE positive control serum). Twelve of
the discordant results (71%) were in the lowest dilution classiﬁed
as positive by the FAVN assay (0.5 IU/ml), one (5.9%) fell within the
0.66 IU/ml category, three (17.6%) in the 0.87 IU/ml category and
one (5.9%) scored 1.14 IU/ml by the FAVN assay (Table 3). There
were no discrepant results achieved using the FAVN or pseudotype
assays and samples from the second visit.
Prior tovaccinationat theﬁrst visit, resultsusing thepseudotype
assay classiﬁed 89.9% of the dogs that had never been vaccinated
Table 3
Titres recorded for discordant sera using the FAVN and pseudotype assays.
Sample ID FAVN titre (IU/ml) Pseudotype titre (dilution)
3a 0.5 5
41b 0.5 20
60b 0.5 5
73 0.5 25
75 0.5 5
81 0.5 20
94 0.5 5
157b 0.5 5
171b 0.5 5
189b 0.5 5
198b 0.5 5
200b 0.5 5
69b 0.66 20
42b 0.87 30
102b 0.87 10
165 0.87 30
168 1.14 20
a Vaccination history was not available for this dog (“no record”).
b Serum samples taken from dogs with no rabies vaccination history prior to this
study (“primary”).
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Fig. 3. Radial tree and panels showing degree of glycoprotein identity and viral titre of lyssavirus pseudotypes. The envelope G genes from LBV, MOKV and DUVVwere cloned
into pI.18 and titres were compared with that achieved by pseudotypes bearing the CVS-11 G. Identity of the full-length G amino acid sequence was used to construct the
tree. Viral titres were assessed using GFP carrying pseudotypes and are given in IFU/ml. The branch lengths and scale correspond to the number of amino acid substitutions
per site.
(“primary”) as having inadequate levels of VNAbs (Fig. 2B). This
compares to 81.5% as determined by the FAVNassay (Fig. 2C). There
was a roughly equal split of inadequate vs adequate levels of VNAbs
(48%vs52%) for thedogs thathad receivedoneormore rabies vacci-
nation(s) previously (“booster”) when tested using the pseudotype
assay (Fig. 2B). The discrepant results described above caused this
balance to shift in favour of adequate VNAb levels (36% vs 64%)
when the same sera were analysed by the FAVN assay (Fig. 2C). In
sera from the second visit both assays detected three dogs (2.5%)
that failed to achieve a level of VNAbs that was greater than the
OIE control serum despite receiving the vaccination (Fig. 2D and
E). None of the three dogs had been given a rabies vaccination
prior to this study and their level of circulating VNAbs was inad-
equate at both visits. Analysis of all results showed that the titres
recorded for each serumbyFAVNandpseudotype assays correlated
strongly (r=0.915, p<0.001 [Pearson’s product–moment correla-
tion]; Fig. 2F).
3.3. African lyssavirus pseudotypes for surveillance
We cloned the G gene sequences of LBV, MOKV and DUVV
into our expression plasmid and tested their ability to be incor-
porated into lentiviral pseudotype particles. Using GFP as a marker
for infection of BHK cells we observed comparable titres for LBV
and MOKV pseudotypes as we achieved using CVS-11 (3.3×105,
3.6×105 and 3.2×105 IFU/ml, respectively; Fig. 3). The titre
recorded for pseudotypes expressing the DUVV G was 1.5-fold
higher at 5.2×105 IFU/ml. To test the speciﬁcity of these African
lyssavirus pseudotypes, neutralisation assays were run with sera
raised against LBV (RV1; serum nos. 1 and 2) and DUVV (RV131;
serum nos. 3, 4, 111 and 112) isolates. Neutralising titres with the
pseudotypes correlated strongly with the titres observed using the
FAVNassay (Table4).Anti-LBVseracross-neutralisedMOKVinboth
the FAVN and pseudotype assays. However, the FAVN assay failed
to detect anti-DUVV VNAb in serum 4 and 111 and only low lev-
els in serum 3 (IC100 =8) compared to the pseudotype assay, which
recorded IC100 titres of 160, 8 and 28 for sera 3, 4 and 111, respec-
tively (Table 4). The negative control and Australian bat lyssavirus
(ABLV) sera did not achieve an IC100 against any genotype, in either
assay, and no cross-neutralisation of DUVV by the LBV sera was
observed (Table 4).
3.4. Utility of rabies (CVS-11) pseudotypes carrying the lacZ
reporter gene
To broaden the lyssavirus pseudotype platform, we cloned the
lacZ gene as a reporter. Using a panel of 33 serum samples selected
to contain low,mediumandhighVNAb titres,we ranparallel assays
and determined that using lacZ as the reporter gene, instead of
luciferase, did not alter the high correlation (r=0.918, p<0.001
[Pearson’s product–moment correlation]; Fig. 4A) or sensitivity and
speciﬁcitywith respect to the titres achieved using the FAVN assay.
While the ﬂexibility to use different read-outs is a key require-
ment of any assay to be used in Africa, it must also be robust, able
towithstand ﬂuctuations in temperatures. Therefore,we tested the
stability of thepseudotype stocks storedunderdifferent conditions.
Freeze-thaw cycles of CVS-11 pseudotypes revealed an average
decrease of 3.7% in viral titre per cycle, while pseudotypes bearing
the VSV or HIV-1 envelope proteins lost 2.6% and 9.2%, respec-
tively (Fig. 4B). Compared to the CVS-11 pseudotype stock stored at
−80 ◦C, aliquots stored at room temperature (average of 23 ◦C) had
a half-life of 1–2 weeks, which increased to 2–4 weeks for aliquots
at+4 ◦C.Pseudotypes storedat−20 ◦Cwere relatively stable forover
6 months (Fig. 4C). This stability was similar to that observed with
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Table 4
Levels of African lyssavirus-neutralising antibodies in sera from immunised rabbits as determined by FAVN and pseudotype assays.
Sample ID Immunogen Lagos bat virus Mokola virus Duvenhage virus
FAVN titre Pseudotype titre FAVN titre Pseudotype titre FAVN titre Pseudotype titre
1 RV 1 (LBV) 128 508 128 640 • •
2 RV 1 (LBV) 362 508 64 80 • •
3 RV 131 (DUVV) • • • • 8 160
4 RV 131 (DUVV) • • • • • 8
5 RV634 (ABLV) • • • • • •
6 Negative control • • • • • •
111 RV 131 (DUVV) • • • • • 28
112 RV 131 (DUVV) • • • • – 12
(•): Failed to record a positive titre. (–): Experiment not undertaken. Titres are given as the geometric mean dilution that achieved an IC100.
Fig. 4. Validation of lacZ-based pseudotypes as a tool for in-ﬁeld diagnostics to
detect neutralising antibodies. (A) Selected samples were run using the lacZ-based
CVS-11 pseudotypes. The results show an identical correlation (r) between the
FAVN results and those achieved using luciferase-based pseudotypes. Sensitivity
(Sn) and speciﬁcity (Sp) relative to the 0.5 IU/ml cut-off are given and r/p values
were calculated using Pearson’s product–moment correlation. The stability of CVS-
11 lacZ-pseudotypes was tested by (B) subjecting aliquots to round of freeze–thaw
or (C) storing aliquots at different temperatures over time. Results for pseudotypes
bearing the VSV and HIV-1 envelope proteins are shown in (B) and CVS-11 pseu-
dotype titres for the time course (C) are given relative to the titre of stocks kept at
−80 ◦C. rt: room temperature.
pseudotypes bearing theVSVenvelope glycoprotein andwas 7-fold
greater than the half-life of pseudotypes bearing the HIV envelope
glycoprotein stored at +4 ◦Cor room temperature (data not shown).
The inclusion of lacZ as a reporter gene increased the applica-
bility of our pseudotype system in resource-limited laboratories as
it allows the determination of VNAb titres without the need for
expensive regents or equipment. Cells were infected with lacZ-
based pseudotypes and subsequently stained with one of three
-gal substrates. Punctate blue staining of infected cell nuclei was
achieved in the presence of X-gal (Fig. 5, far left panels). We also
adapted the assay to allow the -gal colorimetric substrates CPRG
and ONPG to be used (Fig. 5, second left and middle panels).
These changes, and resulting VNAb titres, were recorded using a
microplate reader, reading at 550nm (CPRG) or 405nm (ONPG),
or simply by eye. The incorporation of lacZ is an additional option
to the much used GFP and luciferase reporter genes, which allow a
more high-throughput approach but at a far greater expense (Fig. 5,
second right and far right panels, respectively).
4. Discussion
While mass culling of stray dogs has previously been shown
to be ineffective in controlling the spread of rabies [33,34], this
practice is once again being adopted by a number of countries.
On the contrary, dog vaccination programs have been enormously
successful in controlling canine rabies [35–37], and improved
diagnostics to enable rapid serosurveillance in countries undertak-
ing these programs are therefore important. The assay reported
here offers a practical, effective and robust solution for rapid
lyssavirus serosurveillance. Using lentiviral pseudotypes we can
accurately measure the concentration of VNAbs and, coupled
with the use of lacZ as the reporter gene for pseudotype particle
production, removes the need for high containment laborato-
ries and expensive equipment or reagents. This allows the assay
to be undertaken in laboratories previously unable to use the
existing FAVN. Furthermore, the assay is not just restricted to
lyssavirus serosurveillance as other highly pathogenic viruses that
have been pseudotyped could be incorporated into this platform
[24,38–41].
To our knowledge this is the largest study published to date
using pseudotypes in a diagnostic format for serosurveillance. Of
the 319 samples received, titres for three could not be determined
using the pseudotype assay: one had low level contamination and
two caused cellular cytotoxicity in the assay. These issues were
overcome using higher concentrations of antibiotics and increas-
ing the number of BHK cells used 2-fold, to 2×104 per assay. In
comparison, there were 12 samples that could not be titrated with
the FAVN assay because of insufﬁcient serum volume.While serum
volume varied between samples, there was sufﬁcient volume for
each sample to run duplicate pseudotype neutralisation assays.
This highlights another major advantage of using pseudotypes as
surrogate viruses in neutralisation assays, only small serum vol-
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Fig. 5. Repertoire of reporter genes that can be carried within pseudotypes. We have expanded the range of reporter genes to enable the neutralisation assay to be performed
in a much greater number of laboratories than previously possible. LacZ-based pseudotypes can be detected with X-gal, CPRG or ONPG -gal substrates that turn blue, red
or yellow in the presence of the enzyme, respectively. GFP appears as green cytoplasmic staining while the oxidation of the luciferase substrate results in light emission that
can be detected in a luminometer. [VNAb]: virus-neutralising antibody concentration. The arrow indicates zero luciferase activity.
umes (5–10-fold less than live virus assays) are required for each
assay.
An additional important beneﬁt of pseudotypes is the ﬂexibility
to choose the reporter gene depending on the operator’s require-
ments. For this study, luciferase-based CVS-11 pseudotypes were
used, which allowed high-throughput screening of the samples.
This permitted many plates to be analysed in a short period, how-
ever, both the luciferase reagent and the plate reader are expensive.
In contrast, the reagent for the lacZ reporter system is over 30 times
less expensive than that for luciferase and 3 times less expensive
than the ﬂuorescein isothiocyanate conjugate used in the FAVN
assay. Additionally, as neutralisation assays using pseudotypes are
safer, not requiring BSL3/SAPO 4 facilities, the overall cost of using
them is many fold lower compared to performing the FAVN assay,
thereby allowing expansion of rabies serosurveillance in resource-
limited laboratories. In addition, since pseudotypes carrying the
lacZ reporter can be detected using X-gal, CPRG or ONPG, the
ﬂexibility of the assay is further increased. With colorimetric sub-
strates it is possible to record VNAb titres by simply looking at the
assay plate and recording the colour change. Neutralisation assays
using pseudotypes with lacZ as the reporter can also be used for
semi-high-throughput screening when using an ELI-SPOT (X-gal
staining) or microplate reader (CPRG and ONPG staining). How-
ever, the ﬂexibility offered by packaging lacZ, GFP or luciferase into
the pseudotype particle alonemakes this assay an attractive option
for use in any laboratory undertaking lyssavirus serosurveillance.
The stability of pseudotypes reported here alsomakes this assay
suitable for use in countries where the infrastructure and cold-
chain may be unreliable. If the stocks of pseudotype particles were
to be thawed and re-frozen or to be stored at temperatures below
−80 ◦C, they would still be viable for use in subsequent neutral-
isation assays. This is a major advantage over live virus, where
the virus titre decreases rapidly on freeze-thaw or storage above
−80 ◦C. However, where possible stocks of pseudotypes should be
maintained at −80 ◦C and stored in aliquots to reduce the number
of times each vial is thawed. A future consideration is to freeze dry
thepseudotypeparticles toavoid cold-chain storageand to increase
ease of transport.
The number of inadequate versus adequate vaccine responders,
detected by both types of assays, was comparable at either visit for
collection of serum. However, 17 discordant results were observed
between the pseudotype and FAVN assays, which can partially
be explained by the fact that they were all close to the 0.5 IU/ml
threshold. Assay variability with the FAVN assay means that sam-
ples scoring 0.5 IU/ml had a variable range of 0.38–0.66 IU/ml if
the test was repeated. Twelve out of these 17 samples that had
a 0.5 IU/ml titre in the FAVN assay might have been classiﬁed
as negative if re-tested, which would result in a new sensitiv-
ity score of 98.3%. Conversely, it is also possible that the scores
of 0.38–0.66 IU/ml obtained with the FAVN assay and the corre-
sponding titres achieved using the pseudotype assay could change
if re-tested. It is worth noting the 17 dogs that were classiﬁed as
having inadequate VNAb responses using the pseudotype assay, in
disagreement with the FAVN results, were sampled before vacci-
nation in this trial. In addition, 10 out of the 17 samples were from
dogs with no history of previous rabies vaccination and 6 had been
vaccinated ≥1 year before the study began, therefore their levels of
VNAbs could have decreased over time. One did not have a vaccina-
tion history collected during the trial (#3). These discordant results
coupled with neutralisation data showing DUVV pseudotypes can
detect VNAb in anti-DUVV serum not detected by the FAVN assay
suggests that the pseudotype assay may be more speciﬁc and sen-
sitive for detection of seroconversion than the FAVN assay when a
0.5 IU/ml cut-off is used. However, to conﬁrm this observation fur-
ther studies are required using analogous viral isolates and serum,
and larger sample sizes.
The introduction of the LBV, MOKV and DUVV G as binding anti-
gens into our pseudotype platform, coupled with existing CVS-11,
EBLV-1 and EBLV-2 pseudotypes, means that serum can now be
screened todetectVNAbsagainst sixdifferent lyssavirusgenotypes.
This is of particular importance because large proportions of these
assays are performed on sera from bats, from which only small
volumes of serum are available.
At a time when emerging infectious disease outbreaks are
becoming more frequent and have the potential to spread faster
through international travel, technological advances in infectious
disease research are making assays more rapid facilitating more
automation. However, countries where the outbreaks are most
likely to occur are often unable to utilise these new techniques. We
have addressed these limitations by developing an assay that can
be used for infectious disease serosurveillance and for monitoring
vaccine responses within low-containment laboratories. Neutral-
isation assays based on pseudotypes as a source of target antigen
are a useful platform to use at the start of a new outbreak, not only
for rabies, but also other enveloped RNA viruses such as SARS coro-
naviruses, inﬂuenza and Ebola viruses. Incorporating the lyssaviral
envelope protein (G) into the pseudotype platform creates an assay
that allows rapid screening and vaccine evaluation to be performed
within weeks of the start of an epidemic.
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